Targeting cancers with tyrosine kinase inhibitors: Lessons learned from chronic myeloid leukaemia

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 6, Issue 6, 2006, Pages 526-528

  Mughal, Tariq I ^a,c   Goldman, John M ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; NILOTINIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB;

BRAIN METASTASIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER REGRESSION; CHROMOSOME 22Q; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG APPROVAL; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TARGETING; EDITORIAL; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOMA; MOLECULAR BIOLOGY; PATHOGENESIS; PHILADELPHIA 1 CHROMOSOME; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

EID: 33845982249     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.6-6-526     Document Type: Editorial

References (17)

1. Mughal TI, Goldman JM. Molecularly targeted therapy for chronic myeloid leukemia: beyond the imatinib era. Front Biosci 2006;11:209-20.
2. Druker BJ. Circumventing resistance to kinase-inhibitor therapy. N Engl J Med 2006;354:2594-6.
3. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
4. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med 2003;348:994-1004.
5. Druker BJ, Guilhot F, O'Brien SG et al. Long-term benefits of imatinib for patients newly diagnosed with chronic myelogenous leukemia in chronic-phase: the 5-year update from the IRIS study. J Clin Oncol 2006;24:18S abstract 6506.
6. Mughal TI, Goldman JM. Chronic myeloid leukemia: why does it evolve from a chronic phase to blast phase? Front Biosci 2006;11:198-208.
7. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105: 2640-53.
8. Goldman JM, Mughal TI. Chronic myeloid leukaemia. In: Hoffbrand AV, Catovsky D, Tuddenham EGD (eds), Postgraduate haematology, 5th edn. Oxford: Blackwell Publishing, 2005.
9. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
10. Talpaz M, Shah NP, Kantarjian H et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354: 2531-41.
11. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to geftinib therapy. Science 2004;304: 1497-500.
12. Burton A. What went wrong with Iressa? Lancet Oncology 2003;3:708.
13. Blackball F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer? Lancet Oncol 2006;7:499-507.
14. Burstein HJ, Winer EP, HER2 or not HER2: that is the question. J Clin Oncol 2005;16:3656-9.
15. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005;353:1734-6.
16. Burns HA, Hurwitz HI, Dees EC et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2006;23:5305-13.
17. Coiffier B. Standard treatment of advanced-stage large B-cell lymphoma. Semin. Hematol 2006;43:213-20.